Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Current State of Immunotherapy for Treatment of Glioblastoma.

McGranahan T, Therkelsen KE, Ahmad S, Nagpal S.

Curr Treat Options Oncol. 2019 Feb 21;20(3):24. doi: 10.1007/s11864-019-0619-4. Review.

2.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

3.

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.

PMID:
26454859
4.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
5.

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.

Ishikawa E, Yamamoto T, Matsumura A.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):321-330. doi: 10.2176/nmc.nmc.ra.2016-0334. Epub 2017 May 24. Review.

6.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
7.

The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.

8.

New Approaches for Immune Directed Treatment for Ovarian Cancer.

Hardwick N, Frankel PH, Cristea M.

Curr Treat Options Oncol. 2016 Mar;17(3):14. doi: 10.1007/s11864-016-0389-1. Review.

PMID:
26942589
9.

From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?

Madden DL.

Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5. Review.

PMID:
29411148
10.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

11.

The spectrum of vaccine therapies for patients with glioblastoma multiforme.

Aguilar LK, Arvizu M, Aguilar-Cordova E, Chiocca EA.

Curr Treat Options Oncol. 2012 Dec;13(4):437-50. doi: 10.1007/s11864-012-0208-2. Review.

12.

Immune Checkpoint in Glioblastoma: Promising and Challenging.

Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, Chen J.

Front Pharmacol. 2017 May 9;8:242. doi: 10.3389/fphar.2017.00242. eCollection 2017. Review.

13.

PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Oh T, Ivan ME, Sun MZ, Safaee M, Fakurnejad S, Clark AJ, Sayegh ET, Bloch O, Parsa AT.

Immunotherapy. 2014;6(6):737-53. doi: 10.2217/imt.14.35. Review.

14.

Vaccine therapies for patients with glioblastoma.

Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT.

J Neurooncol. 2014 Sep;119(3):531-46. doi: 10.1007/s11060-014-1502-6. Epub 2014 Aug 28. Review.

PMID:
25163836
15.

Advances in immunotherapy for the treatment of glioblastoma.

Tivnan A, Heilinger T, Lavelle EC, Prehn JH.

J Neurooncol. 2017 Jan;131(1):1-9. doi: 10.1007/s11060-016-2299-2. Epub 2016 Oct 14. Review.

16.

Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.

Authier A, Farrand KJ, Broadley KW, Ancelet LR, Hunn MK, Stone S, McConnell MJ, Hermans IF.

Int J Cancer. 2015 Jun 1;136(11):2566-78. doi: 10.1002/ijc.29309. Epub 2014 Nov 12.

17.

Current vaccine trials in glioblastoma: a review.

Xu LW, Chow KK, Lim M, Li G.

J Immunol Res. 2014;2014:796856. doi: 10.1155/2014/796856. Epub 2014 Apr 3. Review.

18.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

PMID:
29405038
19.

Virus-Based Immunotherapy of Glioblastoma.

Martikainen M, Essand M.

Cancers (Basel). 2019 Feb 5;11(2). pii: E186. doi: 10.3390/cancers11020186. Review.

20.

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.

Yelton CJ, Ray SK.

Neuroimmunol Neuroinflamm. 2018;5. pii: 46. doi: 10.20517/2347-8659.2018.58. Epub 2018 Nov 12.

Supplemental Content

Support Center